ClearPoint Neuro price target raised to $15 from $14 at B. Riley

B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $15 from $14 and keeps a Buy rating on the shares following the Q3 report. The firm sees continued momentum across the company’s diversified business.